Key Influencer in the Pneumococcal Vaccine Market 2025: Rising Prevalence Of Pneumococcal Contamination Drives Growth In Pneumococcal Vaccine Market Driver

What combination of drivers is leading to accelerated growth in the pneumococcal vaccine market?
The escalating occurrence of pneumococcal infections is projected to boost the pneumococcal vaccine market's growth. Pneumococcal infections represent any condition triggered by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This includes illnesses like pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine encourages the body to generate antibodies against these bacteria, thereby minimizing or eliminating bacteria and toxins that cause diseases. This protection is particularly crucial for vulnerable groups such as children, the elderly, and those with compromised immune systems. For instance, data from the Center for Disease Control and Prevention, a US-based public health agency, revealed in January 2022 that pneumococcal pneumonia results in approximately 150,000 hospitalizations annually in the US, constituting up to 30% of adult community-acquired pneumonia. Therefore, the rising occurrence of pneumococcal infections is propelling the pneumococcal vaccine market's growth.

Get Your Pneumococcal Vaccine Market Report Here:
https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

What is the projected compound annual growth rate (CAGR) of the pneumococcal vaccine market from 2025 to 2034, and what factors influence it?
The market size for the pneumococcal vaccine has exhibited robust growth in the past years. Its rise is expected to continue, moving from $8.94 billion in 2024 to a projected $9.49 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.2%. The previous growth is due to factors such as the discovery of streptococcus pneumoniae, the public health concern it poses, the push for early vaccination, advancements in healthcare, and adjustments in vaccination policies.

Expectations are high for a robust expansion of the pneumococcal vaccine market in the coming years. It's projected to escalate to a value of $12.12 billion by 2029, boasting a compound annual growth rate (CAGR) of 6.3%. This growth projection is largely ascribed to various contributing factors such as the evolution of pneumococcal strains, ongoing research and development efforts, prioritization of immunization, wider accessibility of vaccines, and the aging population. Noteworthy trends expected to make a significant impact during the forecast period include the development of multivalent vaccines, the prioritization of vaccination for at-risk groups, enhancement of vaccine efficacy, efforts towards education and increasing awareness, and a focus on infant immunization.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What trends are poised to drive the future success of the pneumococcal vaccine market?
The pneumococcal vaccine market is dominated by leading companies using innovation to create new products, thereby enhancing their market profitability. A case in point is Merck & Co Inc., a US pharmaceutical firm that, in July 2023, rolled out the V116 vaccine. This vaccine is designed to combat the eight unique serotypes of Streptococcus pneumoniae that mainly cause pneumococcal disease in adults, exhibiting a better level of immunogenicity for an array of serotypes in adult cohorts than its counterparts. Besides, V116 has proven to induce positive immune responses in individuals irrespective of their previous vaccination status. V116 has been marked as a breakthrough therapy by the U.S. Food and Drug Administration (FDA) and is currently under Phase 3 development.

What are the major segments of the pneumococcal vaccine market and their role in driving growth?
The pneumococcal vaccine market covered in this report is segmented -

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products
2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous
3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels
4) By End User: Pediatrics, Adults

Subsegments:
1) By Prevnar 13: Pediatric Formulation, Adult Formulation
2) By Synflorix: Pediatric Formulation, Adult Formulation
3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes
4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11950

Which regions are key players in the growth of the pneumococcal vaccine market?
North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the pneumococcal vaccine market?
Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What Is Covered In The Pneumococcal Vaccine Global Market Report?

• Market Size Forecast: Examine the pneumococcal vaccine market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the pneumococcal vaccine market for a structured understanding.
• Key Players Overview: Analyze major players in the pneumococcal vaccine market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the pneumococcal vaccine market.
• Segment Contributions: Evaluate how different segments drive overall growth in the pneumococcal vaccine market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the pneumococcal vaccine market.
• Industry Challenges: Identify potential risks and obstacles affecting the pneumococcal vaccine market.
• Competitive Landscape: Review strategic developments in the pneumococcal vaccine market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.